Latest research
Latest corporate research
Latest tax enhanced reviews
Subscribe to our latest research
What we do
Investment research services
Tax enhanced research services
Bespoke consulting services
About
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
Our team
News & events
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact Us
Twitter icon
Created with Sketch.
×
Latest corporate investment research
Detailed company analysis created specifically for investors
Latest tax enhanced research
Product reports for investors and advisors
Latest published research
Services for corporates
Investment research & analysis
Detailed company analysis created specifically for investors
Services for private Companies
Tax enhanced research
Product reports for investors and advisors.
Bespoke consulting services
Bespoke services
Services for clients with specific needs
About
About Hardman & Co.
We are the longest-established commissioned research provider.
Insights
Group
Created with Sketch.
Podcasts
Group
Created with Sketch.
Videos
Group
Created with Sketch.
Events
Group
Created with Sketch.
See all news
Group
Created with Sketch.
Podcast
The EIS Navigator
Latest Episode
24: Making big ideas investible and measuring impact | Dan Somers of Boundary Capital
Stay up-to-date with the latest research
Sign up to our newsletter
COVID-19: -
Our Commitment to Client Service & Investor Communications
Latest research
Our research can still be accessed for free under MIFID II.
Find out more >
All research
Corporate research
- Update
- Monthly Report
- Sector Report
Tax enhanced research
- VCT
- EIS
- SEIS
- Initiation
All sectors
Agriculture
Building & Construction
Consumer
Financials
Industrial
Infrastructure
Investment Companies
Life Sciences
Media
Mining
Oil & Gas
Property
Renewables
Services
Technology
Transportation
Utilities
List companies
Oxford BioMedica
Life Sciences
Bioverativ deal – establishes structure
By
Dr Dorothea Hill
24 Feb 2018
Primary Health Properties
Property
Strong 2017 results and prospects
By
Mike Foster
22 Feb 2018
City of London Investment Group
Financials
Still correcting upwards
By
Dr Brian Moretta
20 Feb 2018
Allergy Therapeutics plc
Life Sciences
Grass allergy vaccine data imminent
By
Dr Martin Hall
16 Feb 2018
Scancell Holdings
Life Sciences
Validating and de-risking of multiple opportunities
By
Dr Martin Hall
15 Feb 2018
Redx Pharma
Life Sciences
Entering the clinical stage
By
Dr Martin Hall
14 Feb 2018
Bionomics Ltd
Life Sciences
Channelling expertise in CNS drugs
By
Dr Martin Hall
07 Feb 2018
LondonMetric Property
Property
Income compounder: the logistical investor
By
Mike Foster
05 Feb 2018
Schroder European REIT
Property
5.5% prospective dividend yield, triple underpinned
By
Mike Foster
05 Feb 2018
Allergy Therapeutics plc
Life Sciences
Growth in a tough market
By
Dr Martin Hall
02 Feb 2018
Alliance Pharma Plc
Life Sciences
2017: strong operational cashflow
By
Dr Martin Hall
29 Jan 2018
Prev
1
...
40
41
42
43
44
...
52
Next
